To strengthen its women’s health and biosimilars portfolio, Sun Pharma has agreed to acquire Organon in a deal valued at up to US$11.75 B. The acquisition provides Sun Pharma with access to a portfolio of more than 70 Women’s Health and General Medicine products, including biosimilars, marketed across 140 countries. The deal comes five years after Organon was spun‑off from Merck & Co. in 2021. The transaction will be carried out through a merger between Organon and a Sun Pharma subsidiary, with Organon remaining as the surviving entity, and is expected to be completed in early 2027.